BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 36263033)

  • 1. Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis.
    Jou E; Rodriguez-Rodriguez N; McKenzie ANJ
    Front Immunol; 2022; 13():981479. PubMed ID: 36263033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for
    Jou E; Rodriguez-Rodriguez N; Ferreira AF; Jolin HE; Clark PA; Sawmynaden K; Ko M; Murphy JE; Mannion J; Ward C; Matthews DJ; Buczacki SJA; McKenzie ANJ
    Sci Immunol; 2022 Jun; 7(72):eabn0175. PubMed ID: 35658010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis.
    Zhang Y; Davis C; Shah S; Hughes D; Ryan JC; Altomare D; Peña MM
    Mol Carcinog; 2017 Jan; 56(1):272-287. PubMed ID: 27120577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer.
    Dmitrieva-Posocco O; Dzutsev A; Posocco DF; Hou V; Yuan W; Thovarai V; Mufazalov IA; Gunzer M; Shilovskiy IP; Khaitov MR; Trinchieri G; Waisman A; Grivennikov SI
    Immunity; 2019 Jan; 50(1):166-180.e7. PubMed ID: 30650375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8
    Wan J; Wu Y; Huang L; Tian Y; Ji X; Abdelaziz MH; Cai W; Dineshkumar K; Lei Y; Yao S; Sun C; Su Z; Wang S; Xu H
    Cancer Lett; 2021 Apr; 502():34-43. PubMed ID: 33429004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer.
    Pastille E; Wasmer MH; Adamczyk A; Vu VP; Mager LF; Phuong NNT; Palmieri V; Simillion C; Hansen W; Kasper S; Schuler M; Muggli B; McCoy KD; Buer J; Zlobec I; Westendorf AM; Krebs P
    Mucosal Immunol; 2019 Jul; 12(4):990-1003. PubMed ID: 31165767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer.
    Landskron G; De la Fuente López M; Dubois-Camacho K; Díaz-Jiménez D; Orellana-Serradell O; Romero D; Sepúlveda SA; Salazar C; Parada-Venegas D; Quera R; Simian D; González MJ; López-Köstner F; Kronberg U; Abedrapo M; Gallegos I; Contreras HR; Peña C; Díaz-Araya G; Roa JC; Hermoso MA
    Front Immunol; 2019; 10():1394. PubMed ID: 31281317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice.
    Wong SH; Zhao L; Zhang X; Nakatsu G; Han J; Xu W; Xiao X; Kwong TNY; Tsoi H; Wu WKK; Zeng B; Chan FKL; Sung JJY; Wei H; Yu J
    Gastroenterology; 2017 Dec; 153(6):1621-1633.e6. PubMed ID: 28823860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-126 downregulates CXCL12 expression in intestinal epithelial cells to suppress the recruitment and function of macrophages and tumorigenesis in a murine model of colitis-associated colorectal cancer.
    Wu S; Yuan W; Luo W; Nie K; Wu X; Meng X; Shen Z; Wang X
    Mol Oncol; 2022 Oct; 16(19):3465-3489. PubMed ID: 35363937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.
    Lu B; Yang M; Wang Q
    J Mol Med (Berl); 2016 May; 94(5):535-43. PubMed ID: 26922618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth.
    De Simone V; Franzè E; Ronchetti G; Colantoni A; Fantini MC; Di Fusco D; Sica GS; Sileri P; MacDonald TT; Pallone F; Monteleone G; Stolfi C
    Oncogene; 2015 Jul; 34(27):3493-503. PubMed ID: 25174402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-22 promotes the proliferation of cancer cells in smoking colorectal cancer patients.
    Song B; Ma Y; Liu X; Li W; Zhang J; Liu J; Han J
    Tumour Biol; 2016 Jan; 37(1):1349-56. PubMed ID: 26293897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and Colorectal Cancer.
    Sedlak JC; Yilmaz ÖH; Roper J
    Annu Rev Pathol; 2023 Jan; 18():467-492. PubMed ID: 36323004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
    Jou E
    Explor Target Antitumor Ther; 2023; 4(3):474-497. PubMed ID: 37455828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant and Conflicting Correlation of IL-9 With
    Niccolai E; Russo E; Baldi S; Ricci F; Nannini G; Pedone M; Stingo FC; Taddei A; Ringressi MN; Bechi P; Mengoni A; Fani R; Bacci G; Fagorzi C; Chiellini C; Prisco D; Ramazzotti M; Amedei A
    Front Immunol; 2020; 11():573158. PubMed ID: 33488574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy: Dual roles and perspective for clinical treatment of colorectal cancer.
    Zhang Y; Li H; Lv L; Lu K; Li H; Zhang W; Cui T
    Biochimie; 2023 Mar; 206():49-60. PubMed ID: 36244578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations.
    Ingram N; Northwood EL; Perry SL; Marston G; Snowden H; Taylor JC; Scott N; Bishop DT; Coletta PL; Hull MA
    Carcinogenesis; 2013 Oct; 34(10):2341-9. PubMed ID: 23784081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17 and colorectal cancer: From carcinogenesis to treatment.
    Razi S; Baradaran Noveiry B; Keshavarz-Fathi M; Rezaei N
    Cytokine; 2019 Apr; 116():7-12. PubMed ID: 30684916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
    Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
    Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.